Mouse models of malignant pleural effusions
More details
Hide details
Postgraduate Student, Master’s Programme in Basic Biomedical Sciences, Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Greece
Postdoctoral Research Fellow, Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Greece
Assistant Professor of Physiology, Principal Investigator Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Greece
Antonia Marazioti   

Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras; Basic Biomedical Sciences Research Building, 2nd floor, Room B40, 1 Asklepiou Str., University Campus (Panepistimioupolis), 26504 Rio, Greece
Pneumon 2013;26(3):216–222
Malignant pleural effusion (MPE) is a common complication of advanced malignancies, particularly lung and breast cancer. The survival time of patients with MPE is often short, with poor quality of life. The pleural space normally contains a thin film of fluid that is regulated by the balance between production from systemic blood vessel filtration and lymphatic absorption. Tumourinduced disturbances of the pleural fluid production and clearance processes result in the development of MPE. Until recently the specific mechanisms underlying pleural fluid accumulation were poorly defined because studies of MPE pathogenesis were limited by a lack of animal models that could reproduce the pathobiology of human MPE. During the past decade, various research groups have established experimental models that mimic human pleural malignancies, including mice models that require either immunocompromised or immunocompetent mice for propagation of human or murine cancer induced-MPE, respectively. The experimental modelling of MPE has provided new insight into the biological behaviour of tumour cells and tumour-host interactions in the pleural cavity, paving the way for improved management of this end-stage condition.
Antony VB, et al. Management of malignant pleural effusions. European Respiratory Journal 2001; 18:402-419.
Antunes G, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58(suppl 2):ii29-38.
Light RW. Pleural diseases 2001. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:42-86.
Roberts ME, et al. Management of a malignant pleural effusion. Thorax 2010; 65(Suppl. 2):ii32-40.
DiBonito L, et al. The positive pleural effusion. A retrospective study of cytopathologic diagnosis with autopsy confirmation. Acta Cytol 1992; 36:329-332.
Stather DR, Tremblay A. Use of tunneled pleural catheters for outpatient treatment of malignant pleural effusions. Current Opinion in Pulmonary Medicine 2007; 13:328-333.
Noppen M, et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000; 162(3 Pt 1):1023-1026.
Zocchi L. Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 2002; 20:1545-1558.
Meyer PC. Metastatic carcinoma of the pleura. Thorax 1966; 21:437-443.
Light R. Diseases of the pleura. Current Opinion in Pulmonary Medicine 1997; 3:303-304.
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Medicine 2012; 15:487-92.
Astoul P, et al. Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologicallyintact patient carcinoma in nude mice. Anticancer Res 1993; 13(6A):1999-2002.
Wang X, et al. A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice. Anticancer Research 1992; 12:1403-6.
Yano S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157:1893-903.
Yeh HH, et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006; 25:4300-4309.
Elkin M, Vlodavsky I. Tail vein assay of cancer metastasis. Curr Protoc Cell Biol 2001; 19:2.
Stathopoulos GT, et al. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006; 34:142-50.
Boehle AS, et al. An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. The Annals of Thoracic Surgery 2000; 69: 1010-1015.
Edakuni N, et al. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Oncology Research 2006; 16:235-43.
Ohta Y, et al. Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats. Int J Oncology 2001; 18:499-505.
Kimura K, et al. Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model. Cancer Immunol Immunotherapy 2000; 49:71-77.
Hatton MWC, et al. Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. The Journal of laboratory and clinical medicine 2002; 139:316-323.
Hsia CC, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010; 181(4): 394-418.
Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005; 205(2): 194-205.
Matsumoto S, et al. Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma. Lung Cancer 2009; 66(1):75-9.
Stathopoulos GT et al. Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis 2008; 25(1):43-51.
Stathopoulos GT, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008; 6(3): 364-71.
Jongsma J, et al. A Conditional Mouse Model for Malignant Mesothelioma. Cancer cell 2008; 13(3): 261-271.
Marazioti A, et al. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion. PloS One 2013; 8(8):e71207.
Hatton MWC, et al. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: effluxing fibrin(ogen) fragments contain antiangiogenic activity. The Journal of laboratory and clinical medicine 2004; 143(4): 241-254.
Hatton MWC, et al. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors. The Journal of laboratory and clinical medicine 2006; 147(1): 27-35.
Stathopoulos GT, et al. Host-derived Interleukin-5 Promotes Adenocarcinoma-induced Malignant Pleural Effusion. Am. J. Respir. Crit. Care Medicine 2010; 182(10): 1273-1281.
Cui R, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung cancer (Amsterdam, Netherlands) 2009; 63(3): 368-374.
Ma X, et al. Establishment of a malignant pleural effusion mouse model with Lewis lung carcinoma cell lines expressing enhanced green fluorescent protein. Zhongguo Fei Ai Za Zhi 2012; 20(15):317-23.
Stathopoulos GT. Standards for Quantitative Assessment of Lung Structure: The Dawn of. Stereopneumology. Pneumon 2010; 23:34-45.
Stathopoulos GT, et al. Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion. Cancer Research 2007; 67(20): 9825-9834.
Stathopoulos GT, et al. A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion. Journal of the National Cancer Institute 2008; 100(20): 1464-1476.
Moschos C, et al. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia 2009; 11(3): 298-304.
Kraus-Berthier L, et al. Histology and Sensitivity to Anticancer Drugs of Two Human Non-Small Cell Lung Carcinomas Implanted in the Pleural Cavity of Nude Mice. Clinical Cancer Research 2000; 6(1): 297-304.
Stathopoulos GT, et al. Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion. Am. J. Respir. Crit. Care Med. 2008; 178(1): 50-59.
Psallidas I, et al. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol. Cancer 2010; 9: 56.
Moschos C, et al. A sulindac analogue is effective against malignant pleural effusion in mice. Lung Cancer 2011; 73(2): 171-175.